导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 26.09% | 217/4773 |
| 近一周 | 0.84% | 558/5465 |
| 近一月 | -4.83% | 3487/5421 |
| 近一季 | -10.59% | 3783/5231 |
| 近半年 | 21.73% | 186/4920 |
| 近一年 | 28.83% | 255/4394 |
| 近两年 | 155.41% | 212/2954 |
| 近三年 | 122.05% | 83/2253 |
| 成立以来 | 95.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.15% 4045/4961 |
81.59% 174/5312 |
- - |
- - |
| 2025 | 43.67% 657/4813 |
1.89% 1521/3635 |
-0.36% 2904/4076 |
50.67% 297/4524 |
-6.08% 3669/4813 |
| 2024 | 22.26% 389/3463 |
-5.31% 1868/2808 |
2.42% 351/3014 |
13.44% 2167/3129 |
11.13% 237/3463 |
| 2023 | 5.29% 192/2656 |
18.46% 161/2280 |
-3.16% 749/2385 |
-8.12% 1664/2515 |
-0.10% 179/2655 |
| 2022 | -36.03% 1737/2207 |
-23.86% 1747/1919 |
0.35% 1558/2016 |
-18.12% 1684/2113 |
2.25% 1000/2208 |
| 2021 | 9.83% 450/1822 |
-8.32% 1081/1255 |
20.23% 152/1330 |
-8.57% 1140/1466 |
8.98% 132/1822 |
| 2020 | 39.66% 328/1250 |
-1.07% 202/1028 |
27.89% 121/1067 |
3.39% 985/1164 |
6.77% 744/1184 |
| 2019 | 67.69% 33/1092 |
40.81% 45/739 |
-12.00% 781/788 |
21.23% 6/850 |
11.63% 52/918 |
| 2018 | -37.58% 600/834 |
- - |
-14.98% 509/631 |
-12.40% 613/660 |
-15.83% 625/682 |
| 2017 | 19.25% 196/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.58% 422/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证电子ETF联接C VS. 长安沪深300非周期A(740101) |